Anest. intenziv. Med. 2023;34(1):8-14 | DOI: 10.36290/aim.2023.003

Medical cannabis ad its significance for current medicineReview Article

Landa L.1, 2, Juřica J.1, 4, 5, Trojan V.2, Demlová R.1, 4, Hřib R.2, 3
1 Farmakologický ústav, Lékařská fakulta, Masarykova univerzita, Brno
2 Cannabis Facility, Mezinárodní centrum klinického výzkumu při Fakultní nemocnici u sv. Anny v Brně
3 Centrum pro léčbu bolesti, ARK, Fakultní nemocnice u sv. Anny v Brně
4 Masarykův onkologický ústav, Brno
5 Ústav farmakologie a toxikologie, Farmaceutická fakulta, Masarykova univerzita, Brno

Since the recent changes in legislation, it is presently possible to use cannabis for medical purposes and there is an increasing interest in this mode of treatment. This review describes brief history of cannabis use and basic classification of substances found in the plant. It is focused on pharmacodynamics and pharmacokinetics of the main cannabinoids THC and CBD, with note on definition and significance of endocannabinoid system. Practically used routes of administration and drug dosage forms are mentioned as well. Furthermore, the article concisely summarizes specializations of physicians, who can prescribe medical cannabis, its main indications, adverse effects and contraindications, including aspect of safe driving in patients with this treatment. The last part of this review is aimed at therapy of pain and it brings two case reports of real patients treated with medical cannabis.

Keywords: cannabis, THC, CBD, pain treatment.

Received: January 16, 2023; Revised: January 16, 2023; Accepted: February 13, 2023; Published: April 25, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Landa L, Juřica J, Trojan V, Demlová R, Hřib R. Medical cannabis ad its significance for current medicine. Anest. intenziv. Med. 2023;34(1):8-14. doi: 10.36290/aim.2023.003.
Download citation

References

  1. Laursen L. Botany: The cultivation of weed. Nature. 2015;525:S4-S5. Go to original source...
  2. Zuardi AW. History of cannabis as a medicine: a review. Bras. J. Psychiatry. 2006;28(2): 153-157. Go to original source...
  3. Kalant H. Medicinal use of cannabis: history and current status. Pain Res. Manag. 2001;(2):80-91. Go to original source...
  4. Dreher J. Psychofarmakoterapie. Překlad 2. vydání. Praha: Grada Publishing; 2017. ISBN 978-80-271-0133-7.
  5. Abuhasira R, Shbiro L, Landschaft Y. Medical use of cannabis and cannabinoids containing products - Regulations in Europe and North America. Eur. J. Intern. Med. 2018;49:2-6. Go to original source...
  6. [Internet] Státní agentura pro konopí pro léčebné účely. Available from: https://www.sakl.cz/konopi/.
  7. Mechoulam R, Gaoni Y. Recent advances in the chemistry of hashish. Fortschr. Chem. Org. Naturst. 1967;25:175-213. Go to original source... Go to PubMed...
  8. Elsohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci. 2005;78(5):539-548. Go to original source...
  9. Devane WA, Hanuš L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258(5090):1946-1949. Go to original source...
  10. Šulcová A, Landa L. Farmakodynamika kanabinoidů a přehled jejich možného terapeutického využití. In: Landa L. (ed.) Léčebné konopí v současné medicínské praxi. Praha: Grada Publishing; 2020, 58-67. ISBN 978-80-247-3967-0.
  11. Storozhuk MV, Zholos AV. TRP Channels as novel targets for endogenous ligands: Focus on endocannabinoids and nociceptive signalling. Curr. Neuropharmacol. 2018;16(2):137-150. Go to original source... Go to PubMed...
  12. Lowe H, Toyang N, Steele B, Bryant J, Ngwa W. The endocannabinoid cystem: A potential target for the treatment of various diseases. Int. J. Mol. Sci. 2021; 22(17):9472. Go to original source... Go to PubMed...
  13. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 1964;86(8):1646-1647. Go to original source...
  14. Le Boisselier R, Alexandre J, Lelong­‑Boulouard V, Debruyne D. Focus on cannabinoids and synthetic cannabinoids. Clin. Pharmacol. Ther. 2017;101(2):220-229. Go to original source...
  15. Morales P, Hurst DP, Reggio PH. Molecular targets of the phytocannabinoids: A complex picture. Prog. Chem. Org. Nat. Prod. 2017;103:103-131. Go to original source...
  16. Preedy VR. Handbook of Cannabis and related pathologies: Biology, Pharmacology, Diagnosis, and Treatment. London: Academic Press; 2017. ISBN 978-0-12-800756-3
  17. Mechoulam R, Shvo Y. The structure of cannabidiol. Tetrahedron. 1963;19(12):2073-2078. Go to original source... Go to PubMed...
  18. Peng J, Fan M, An C, Ni F, Huang W, Luo J. A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD). Basic. Clin. Pharmacol. Toxicol. 2022;130(4):439-456. Go to original source...
  19. Laprairie RB, Bagher AM, Kelly ME, Denovan­‑Wright EM. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br. J. Pharmacol. 2015;172(20):4790-4805. Go to original source...
  20. Morales P, Hurst DP, Reggio PH. Molecular targets of the phytocannabinoids: A complex picture. Prog. Chem. Org. Nat. Prod. 2017;103:103-31. Go to original source...
  21. Ghovanloo MR, Shuart NG, Mezeyova J, Dean RA, Ruben PC, Goodchild SJ. Inhibitory effects of cannabidiol on voltage­‑dependent sodium currents. J. Biol. Chem. 2018;293(43):16546-16558. Go to original source...
  22. Rodriguez­‑Munoz M, Onetti Y, Cortes­‑Montero E, Garzon J, Sanchez­‑Blazquez P. Cannabidiol enhances morphine antinociception, diminishes NMDA­‑mediated seizures and reduces stroke damage via the sigma 1 receptor. Mol Brain. 2018;11(1):51. Go to original source... Go to PubMed...
  23. Hanuš L, Šulcová A, Landa L. Kanabinoidní látky a léčivá síla konopí. In: Landa L. (ed.) Léčebné konopí v současné medicínské praxi. Praha: Grada Publishing; 2020, 38-57. ISBN 978-80-247-3967-0.
  24. Calapai F, Cardia L, Esposito E, Ammendolia I, Mondello C, Lo Giudice R, et al. Pharmacological aspects and biological effects of cannabigerol and its synthetic derivatives. Evid. Based. Complement. Alternat. Med. 2022;3336516. Go to original source... Go to PubMed...
  25. Juřica J. Farmakokinetika a lékové interakce kanabinoidů. In: Landa L. (ed.) Léčebné konopí v současné medicínské praxi. Praha: Grada Publishing; 2020, 68-82. ISBN 978-80-247-3967-0.
  26. Gaston TE, Friedman D. Pharmacology of cannabinoids in the treatment of epilepsy. Epilepsy Behav. 2017;70(Pt B):313-318. Go to original source...
  27. Harvey DJ, Samara E, Mechoulam R. Urinary metabolites of cannabidiol in dog, rat and man and their identifi cation by gas chromatography­‑mass spectrometry. J. Chromatogr. 1991;562(1-2):299-322. Go to original source... Go to PubMed...
  28. Newmeyer MN, Swortwood MJ, Barnes AJ, Abulseoud OA, Scheidweiler KB, Huestis MA. Free and glucuronide whole blood cannabinoids' pharmacokinetics after controlled smoked, vaporized, and oral cannabis administration in frequent and occasional cannabis users: Identification of recent cannabis intake. Clin. Chem. 2016;62(12):1579-1592. Go to original source...
  29. MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur. J. Intern. Med. 2018;49:12-19. Go to original source...
  30. Vandrey R, Herrmann ES, Mitchell JM, Bigelow GE, Flegel R, LoDico C, et al. Pharmacokinetic profi le of oral cannabis in humans: Blood and oral fluid disposition and relation to pharmacodynamic outcomes. J. Anal. Toxicol. 2017;41(2):83-99. Go to original source... Go to PubMed...
  31. van den Elsen GA, Ahmed AI, Lammers M, Kramers C, Verkes RJ, van der Marck MA, et al. Efficacy and safety of medical cannabinoids in older subjects: a systematic review. Ageing Res. Rev. 2014;14:56-64. Go to original source...
  32. Trojan V, Landa L, Hrib R, Jurica J, Rychlickova J, Zvonicek V, et al. Assessment of delta-9-tetrahydrocannabinol (THC) in saliva and blood after oral administration of medical cannabis with respect to its effect on driving abilities. Physiol. Res. 2022 Nov 28;71(5):703-712. Go to original source... Go to PubMed...
  33. Landa L, Jurica J, Sliva J, Pechackova M, Demlova R. Medical cannabis in the treatment of cancer pain and spastic conditions and options of drug delivery in clinical practice. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2018;162(1):18-25. Go to original source... Go to PubMed...
  34. [Internet] Státní agentura pro konopí pro léčebné účely. Available from: http://www.sakl.cz/lekari/informace­‑pro­‑lekare.
  35. [Internet] Státní agentura pro konopí pro léčebné účely. Available from: http://www.sakl.cz/pacienti/nezadouci.
  36. Hřib R, Pecháčková M, Šaloun J. Kanabinoidy v léčbě chronické neonkologické bolesti. In: Landa L. (ed.) Léčebné konopí v současné medicínské praxi. Praha: Grada Publishing; 2020, 83-96. ISBN 978-80-247-3967-0.
  37. Aviram J, Pud D, Gershoni T, Schiff­‑Keren B, Ogintz M, Vulfsons S, et al. Medical cannabis treatment for chronic pain: Outcomes and prediction of response. Eur. J. Pain. 2021;25(2):359-374. Go to original source...
  38. Abelev S, Warne LN, Benson M, Hardy M, Nayee S, Barlow J. Medicinal Cannabis for the Treatment of Chronic Refractory Pain: An Investigation of the Adverse Event Profile and Health­‑Related Quality of Life Impact of an Oral Formulation. Med Cannabis Cannabinoids. 2022 Feb 9;5(1):20-31. doi: 10.1159/000521492. PMID: 35950052; PMCID: PMC9235063. Go to original source... Go to PubMed...
  39. Greis A, Larsen E, Liu C, Renslo B, Radakrishnan A, Wilson­‑Poe AR. Perceived efficacy, reduced prescription drug use, and minimal side effects of cannabis in patients with chronic orthopedic pain. Cannabis Cannabinoid Res. 2022;7(6):865-875. Go to original source... Go to PubMed...
  40. Hjorthøj C, La Cour P, Nordentoft M, Posselt CM. Cannabis­‑based medicines and medical cannabis for patients with neuropathic pain and other pain disorders: Nationwide register­‑based pharmacoepidemiologic comparison with propensity score matched controls. Eur. J. Pain. 2022;26(2):480-491. Go to original source...
  41. Żyga J. A review of studies evaluating medical cannabis for the chronic pain management. J. Educ. Health Sport. 2022;12(8):250-256. Go to original source...
  42. Ng JY, Abrams A, Pathak A, Tahir U, Jomy J. What are the experiences of patients using cannabis for pain? A systematic review of qualitative studies. Eur. J. Integr. Med. 2022;49:102098. Go to original source...




Anesteziologie a intenzivní medicína

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.